These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 20193104)
1. Research progression of CD133 as a marker of cancer stem cells. Zhang H; Li SY Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104 [TBL] [Abstract][Full Text] [Related]
2. CD133 as a marker for cancer stem cells: progresses and concerns. Wu Y; Wu PY Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053 [TBL] [Abstract][Full Text] [Related]
3. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. Bidlingmaier S; Zhu X; Liu B J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640 [TBL] [Abstract][Full Text] [Related]
5. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
6. Targeting CD133 antigen in cancer. Ferrandina G; Petrillo M; Bonanno G; Scambia G Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986 [TBL] [Abstract][Full Text] [Related]
7. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cheng JX; Liu BL; Zhang X Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008 [TBL] [Abstract][Full Text] [Related]
8. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204 [TBL] [Abstract][Full Text] [Related]
9. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572 [TBL] [Abstract][Full Text] [Related]
10. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409 [TBL] [Abstract][Full Text] [Related]
11. Biology and clinical implications of CD133(+) liver cancer stem cells. Ma S Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864 [TBL] [Abstract][Full Text] [Related]
12. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics. Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969 [TBL] [Abstract][Full Text] [Related]
13. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases. Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076 [TBL] [Abstract][Full Text] [Related]
14. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties. Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729 [TBL] [Abstract][Full Text] [Related]
15. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781 [TBL] [Abstract][Full Text] [Related]
16. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Le H; Zeng F; Xu L; Liu X; Huang Y Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911 [TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635 [TBL] [Abstract][Full Text] [Related]
19. CD133: molecule of the moment. Mizrak D; Brittan M; Alison M J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118 [TBL] [Abstract][Full Text] [Related]
20. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]